Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.
Company Details
- Employees
- 17
- Address
- 50 Milk St, Boston,massachusetts 02109,united States
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- http://www.t1dfund.org
- Keywords
- Manager jobs.
- HQ
- Boston, Massachusetts
T1d Fund Questions
T1D Fund's website is http://www.t1dfund.org
T1D Fund's LinkedIn profile is https://www.linkedin.com/company/t1d-fund
T1D Fund has
17 employees.
View email and phone details for 17
employees at T1D Fund.
T1D Fund's industry is
Venture Capital and Private Equity Principals
T1D Fund's top competitors are
Vertex Pharmaceuticals,
Dexcom,
American Diabetes Association,
The Diabetes Link,
Breakthrough T1d,
Jdrf International,
Beyond Type 1,
The Diatribe Foundation,
Tandem Diabetes Care,
T1d Exchange.
T1D Fund's categories are Venture Capital and Private Equity Principals
